Long-term survival in multiple myeloma: A single-center experience

Clinical and Experimental Medicine

Volumn 8, Issue 3, 2008, Pages 133-139

  Merchionne, Francesca ^a   Procaccio, Pasquale ^a   Dammacco, Franco ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Conventional chemotherapy; Long term survival; Multiple myeloma; Prognostic factors; Response duration

Indexed keywords

ALPHA INTERFERON; ANTIINFECTIVE AGENT; BENCE JONES PROTEIN; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; NAVELBINE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; RISK FACTOR; STEM CELL TRANSPLANTATION; SURVIVAL; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SURVIVAL;

EID: 51749091947     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-008-0169-8     Document Type: Article

References (46)

1. S.V. Rajkumar E. Blood D. Vesole 2006 Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 24 431 436
2. P.G. Richardson P. Sonneveld M.W. Schuster 2005 Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2487 2498
3. S.V. Rajkumar S.R. Hayman M.Q. Lacy 2005 Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma Blood 106 4050 4053
4. R. Alexanian A. Haut A.U. Khan 1969 Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens JAMA 208 1680 1685
5. Myeloma Trialist's Collaborative Group 1998 Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials J Clin Oncol 16 3832 3842
6. A. Ahre M. Bjorkholm H. Mellstedt 1984 Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden Cancer Treat Rep 68 1331 1338
7. F. Mandelli G. Avvisati S. Amadori 1990 Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy N Engl J Med 322 1430 1434
8. M. Attal J.L. Harousseau A.M. Stoppa 1996 A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome N Engl J Med 335 91 97
9. M. Attal J.L. Harousseau T. Facon 2003 Single versus double autologous stem-cell transplantation for multiple myeloma N Engl J Med 349 2495 2502
10. M. Cavo P. Tosi E. Zamagni 2007 Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study J Clin Oncol 25 2434 2441
11. R.A. Kyle 1983 Long-term survival in multiple myeloma N Engl J Med 308 314 316
12. J.P. Dutcher P.H. Wiernik 1984 Long-term survival of a patient with multiple myeloma - a cure? A case report Cancer 53 2069 2072
13. R. Alexanian 1985 Ten-year survival in multiple myeloma Arch Intern Med 145 2073 2074
14. H. Murakami K. Nemoto S. Miyawaki 1992 Ten-year survivors with multiple myeloma J Intern Med 231 129 131
15. J. Tsuchiya H. Murakami T. Kanoh 1994 Ten-year survival and prognostic factors in multiple myeloma. Japan Myeloma Study Group Br J Haematol 87 832 834
16. R. Abe T. Ishibashi T. Shichishima Y. Maruyama 2001 Ten-year survivor with multiple myeloma in first complete remission following treatment with conventional chemotherapy. Case report and a review of the literature Acta Haematol 105 241 243
17. J. Bladé R.A. Kyle P.R. Greipp 1996 Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years Br J Haematol 93 345 351
18. F. Dammacco F. Perosa P. Procaccio 2001 Mieloma multiplo e gammapatie monoclonali: quadri clinici, acquisizioni eziopatogenetiche e progressi terapeutici. Atti 102° Congr Naz Soc Ital Med Int Ann Ital Med Int 16 5s 40s
19. Chronic Leukemia-Myeloma Task Force 1973 Proposed guidelines for clinical studies Cancer Chemother Rep 4 145 158
20. B.G. Durie S.E. Salmon 1975 A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Cancer 36 842 854
21. P.R. Greipp J. San Miguel B.G. Durie 2005 International staging system for multiple myeloma J Clin Oncol 23 3412 3420
22. J. Bladé D. Samson D. Reece 1998 Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant Br J Haematol 102 1115 1123
23. R. Alexanian J. Bonnet E. Gehan 1972 Combination chemotherapy for multiple myeloma Cancer 30 382 389
24. A. Corso C. Klersy M. Lazzarino C. Bernasconi 1998 Multiple myeloma in younger patients: the role of age as prognostic factor Ann Hematol 76 67 72
25. S. Lenhoff M. Hjorth J. Westin 2006 Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group Br J Haematol 133 389 396
26. S.Y. Kristinsson O. Landgren P.W. Dickman 2007 Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003 J Clin Oncol 25 1993 1999
27. A. Anagnostopoulos D. Gika A. Symeonidis 2005 Multiple myeloma in elderly patients: prognostic factors and outcome Eur J Haematol 75 370 375
28. H.J. van de Velde X. Liu G. Chen 2007 Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma Haematologica 92 1399 1406
29. T.M. Oivanen P. Kellokumpu-Lehtinen A.M. Koivisto 1999 Response level and survival after conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study Eur J Haematol 62 109 116
30. A. Riccardi O. Mora C. Tinelli 2003 Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol Eur J Cancer 39 31 37
31. B.G. Durie J. Jacobson B. Barlogie J. Crowley 2004 Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials J Clin Oncol 22 1857 1863
32. A. Osterborg M. Bjorkholm M. Bjoreman 1993 Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden Blood 81 1428 1434
33. D. Cunningham R. Powles J. Malpas 1998 A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results Br J Haematol 102 495 502
34. Myeloma Trialist's Collaborative Group 2001 Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients Br J Haematol 113 1020 1034
35. E. Fritz H. Ludwig 2000 Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients Ann Oncol 11 1427 1436
36. A. Montuoro L. De Rosa A. De Blasio 1990 Alpha-2a-interferon/melphalan/ prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma Br J Haematol 76 365 368
37. B. Klein X.G. Zhang M. Jourdan 1990 Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma Eur Cytokine Netw 1 193 201
38. M. Schwabe A.T. Brini M.C. Bosco 1994 Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha-and beta-chains J Clin Invest 94 2317 2325
39. M. Jourdan X.G. Zhang M. Portier 1991 IFN-alpha induces autocrine production of IL-6 in myeloma cell lines J Immunol 147 4402 4407
40. W. Matsui C.A. Huff M. Vala 2003 Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation Br J Haematol 121 251 258
41. L.M. Knudsen M. Hjorth E. Hippe Nordic Myeloma Study Group 2000 Renal failure in multiple myeloma: reversibility and impact on the prognosis Eur J Haematol 65 175 181
42. A. Corso A. Nozza M. Lazzarino 1999 Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapy Haematologica 84 336 341
43. D.E. Joshua J. Gibson R.D. Brown 1994 Mechanisms of the escape phase of myeloma Blood Rev 8 13 20
44. A. Vacca D. Ribatti M. Presta 1999 Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma Blood 93 3064 3073
45. A. Vacca R. Ria F. Semeraro 2003 Endothelial cells in the bone marrow of patients with multiple myeloma Blood 102 3340 3348
46. C.S. Mitsiades N.S. Mitsiades N.C. Munshi 2006 The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions Eur J Cancer 42 1564 1573